In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the Optimize Heart Failure Care Program

Session Poster Session 3

Speaker Lilyana Mircheva

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : LG Mircheva (Varna,BG), Y T Yotov (Varna,BG)

Authors:
LG Mircheva1 , Y T Yotov1 , 1Medical University - Varna - Bulgaria ,

On behalf: Optimize Heart Failure Care Program

Citation:

Heart failure (HF) affects quality of life (QoL). High heart rate (HR) is an important prognostic factor and worsens further the QoL in patients with HF.

Aim: to assess the benefits of early administration of Ivabradine (Iv) on QoL in patients with HF.

Subjects and methods: Overall, 156 patients at a mean age 68 years, 69% males, were actively followed for 6 months. All patients were evaluated for their demographic data and etiology and by echocardiography at baseline before dehospitalization from the Clinic and lab tests including NTproBNP, quality of life measures, 6-minute walking test (6MWT), NYHA class, and clinical examination at follow-up visits were done.

Results: Iv was administered in 18.4% of all patients, 27% of the patients in sinus rhythm. The administration of Iv improved all measures of QoL (Table1). The distance covered at 6MWT increased more with 53.9 m in Iv group.

Conclusions: The early administration of HR reducing therapy including Iv improve the QoL in all dimensions.

Ivabradine + Ivabradine - P
EF % +3.4 -0.89 NS

% NYHA II

after 6 mo

77 44 0.023
KCCQ units +21.65 +15.7 NS
VAS % +15 +12 NS
EQ5 units +0.13 +0.14 NS

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are